血清miRNA液体活检在早期卵巢癌诊断中的临床价值

Clinical value of serum miRNA liquid biopsy in the diagnosis of early ovarian cancer

目的 探讨血清微RNA(microRNA,miRNA)液体活检在早期卵巢癌诊断中的临床价值。方法 选取2021—2023年湖州市妇幼保健院的22个新鲜冷冻Ⅰ期卵巢癌组织和9个相邻正常卵巢组织用于本研究。使用R软件中的limma软件包分析肿瘤和邻近正常组织之间miRNA的差异表达。利用公开的回顾性血清miRNA测序数据集GSE106817使用Ⅰ期卵巢癌中高表达的miRNA训练Logistic回归模型,使用GSE113486和GSE31568验证模型的准确性。结果 Ⅰ期卵巢癌组织中共筛选出8种高表达miRNA,即miR-182、miR-183、miR-202、miR-205、miR-508、miR-509-3、miR-513B和miR-513C。在训练队列GSE106817中用于诊断卵巢癌的曲线下面积(area under the curve,AUC)为0.89。在验证队列GSE31568和GSE113486中诊断卵巢癌的AUC分别为0.85和0.86。结论 血清miRNA液体活检对早期卵巢癌的诊断有较高的临床价值。

Objective To investigate the clinical value of serum microRNA(miRNA) liquid biopsy in the diagnosis of early ovarian cancer.Methods Twenty-two fresh and frozen stage Ⅰ ovarian cancer tissues and nine adjacent normal ovarian tissues from Huzhou Maternal and Child Health Care Hospital from 2021 to 2023 were selected for this study.Differential expression of miRNA between tumors and adjacent normal tissues was analyzed using limma software package in R software.The published retrospective serum miRNA sequencing dataset GSE106817 was used to train the Logistic regression model with highly expressed miRNA in stage Ⅰ ovarian cancer,and GSE113486 and GSE31568 were used to verify the accuracy of the model.Results A total of 8 highly expressed miRNA were selected from stage Ⅰ ovarian cancer,namely miR-182,miR-183,miR-202,miR-205,miR-508,miR-509-3,miR-513B and miR-513C.The area under the curve(AUC) for diagnosing ovarian cancer in the training cohort GSE106817 was 0.89.The AUC for diagnosis of ovarian cancer in validation cohorts GSE31568 and GSE113486 was 0.85 and 0.86,respectively.Conclusion Serum miRNA liquid biopsy has high clinical value in the diagnosis of early ovarian cancer.